Brokerages expect MediWound Ltd. (NASDAQ:MDWD) to announce sales of $740,000.00 for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for MediWound’s earnings, with the lowest sales estimate coming in at $600,000.00 and the highest estimate coming in at $820,000.00. MediWound reported sales of $520,000.00 in the same quarter last year, which indicates a positive year-over-year growth rate of 42.3%. The company is expected to issue its next quarterly earnings results on Monday, November 13th.

According to Zacks, analysts expect that MediWound will report full-year sales of $740,000.00 for the current financial year, with estimates ranging from $2.50 million to $3.40 million. For the next financial year, analysts anticipate that the company will post sales of $8.70 million per share, with estimates ranging from $5.80 million to $11.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that that provide coverage for MediWound.

MediWound (NASDAQ:MDWD) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.01). The business had revenue of $0.69 million during the quarter, compared to analysts’ expectations of $0.69 million. MediWound had a negative return on equity of 326.32% and a negative net margin of 752.78%. The firm’s quarterly revenue was up 93.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.34) earnings per share.

Several research firms recently weighed in on MDWD. Zacks Investment Research downgraded MediWound from a “hold” rating to a “sell” rating in a report on Tuesday, August 8th. Aegis reiterated a “buy” rating and issued a $11.00 target price on shares of MediWound in a report on Thursday, May 25th. SunTrust Banks, Inc. reiterated a “buy” rating on shares of MediWound in a report on Monday, June 26th. Finally, Jefferies Group LLC set a $10.00 target price on shares of MediWound and gave the stock a “buy” rating in a report on Friday, August 25th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $9.19.

Shares of MediWound (NASDAQ:MDWD) opened at 6.10 on Friday. The stock has a 50 day moving average of $6.37 and a 200-day moving average of $6.53. The stock’s market capitalization is $133.92 million. MediWound has a 52-week low of $4.25 and a 52-week high of $8.58.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/17/zacks-brokerages-expect-mediwound-ltd-mdwd-will-post-quarterly-sales-of-740000-00.html.

A number of institutional investors have recently made changes to their positions in MDWD. Wells Fargo & Company MN grew its stake in shares of MediWound by 19.7% during the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock worth $351,000 after acquiring an additional 8,745 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of MediWound by 1.7% during the first quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock worth $499,000 after acquiring an additional 1,300 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its stake in shares of MediWound by 20.3% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock worth $13,791,000 after acquiring an additional 342,165 shares during the last quarter. Finally, Wellington Management Group LLP grew its stake in shares of MediWound by 11.0% during the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock worth $14,241,000 after acquiring an additional 213,745 shares during the last quarter. Institutional investors and hedge funds own 23.47% of the company’s stock.

MediWound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Get a free copy of the Zacks research report on MediWound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for MediWound (NASDAQ:MDWD)

Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.